OT15 Roc'd PCT/PTO 1.8 JAN 2005



Appl. No.

: National Phase Entry PCT/EP2003/007786

Applicant

: Axel ULLRICH et al

Filed

: Herewith

TC/A.U.

Examiner

: 2923-679

Docket No. Customer No.: 6449

Confirmation No. :

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 <sup>1</sup> Alexandria, VA 22313-1450

F Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report. We understand that the references have been forwarded by the International Bureau, and are available to the Examiner, but if the Examiner needs copies of any of the references, the Examiner is requested to advise counsel accordingly.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

Robert B. Murray

Attorney for Applicant

Registration No. 22,980

ROTHWELL, FIGG, ERNST & MANBECK

1425 K. Street, Suite 800 Washington, D.C. 20005

Telephone: (202) 783-6040

RBM/cb

OT15 Roc'd POT/PTO 18 JAN 2005

				Co ete if Known		
INFORMA <sup>*</sup>	TION DISC	LOSUI	RE	Application Number	National Phase Entry O of PCT/EP2003/007786	
STATEME	NT BY API	PLICA	NT	Filing Date	Herewith	
				First Named Inventor	Axel ULLRICH et al	
				Group Art Unit		
				Examiner Name		
				Confirmation No.		
Sheet		of	3	Attorney Docket Number	2923-679	
				<u>L</u>		

			FOF	REIGN PAT	ENT DOCUMENTS	<u> </u>	
Examiner Cite Initials* No.1		F	Foreign Patent Docu	ment		Date of Publication of	
	Office <sup>3</sup> Number <sup>4</sup> Kind <sup>5</sup> Code (if known)			Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	T	
	1.	wo	92 17608	Α	Walter Birchmeier	10/15/92	
	2.	wo	00 76309	А	Vlaams Interuniversitair Inst	12/21/00	
	3.	wo	01 78778	Α	Vlaams Interuniversitair Inst	10/25/01	
*****							
						<u> </u>	ļ.
<del></del>							-
							$\vdash$
		<u> </u>					$\vdash$
							-
		<u> </u>					$\vdash$
-							┝
		<del> </del>					
							$\vdash$
Examiner Signature			<del>!</del>	<b>!</b>	Date Considered	1	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

DT15 RECEDITION 18 JAN 2005

				Complete if K. n		
INFORMA	TION DISC	LOSU	RE	Application Number	National Phase Entry of PCT/EP2003/007786	
STATEME	STATEMENT BY APPLICANT				Herewith	
				First Named Inventor	Axel ULLRICH et al	
					·	
Sheet		of	3	Attorney Docket Number	2923-679	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the						
Initials*	No. <sup>1</sup>	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²					
	4.	Domagala et al., "Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high KI-67 growth fraction", AMERICAN JOURNAL OF PATHOLOGY, vol. 136, no. 1, 1990, pgs. 219-228.						
	5.	Bachmeier et al., "Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity", ANTICANCER RESEARCH, vol. 21, no. 6A, November 2001, pgs. 3821-3828.						
	6.	Attar et al., "Axl receptor tyrosine kinase expression in human breast cancer", BREAST CANCER RESEARCH AND TREATMENT, (Oct. 1997), vol. 46, no. 1, pp. 91						
	7.	Dodge et al., "MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer", CLINICAL CANCER RESEARCH, 7/11, (3640-3648) November 2001.						
	8.	Fridell et al., "GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 12, 20 March 1998, pgs. 7123-7126.						
	9.	Wu et al., "Clinical significance of AXL kinase family in gastric cancer", ANTICANCER RESEARCH, (2002 Mar-Apr) 22 (2B) 1071-8.						
	10.	Meric et al., "Expression profile of tyrosine kinases in breast cancer", CLINICAL CANCER RESEARCH, 8/2 (361-367), February 2002.						
	11.	Berclaz et al., "Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast", ANNALS OF ONCOLOGY, (2001 Jun) 12 (6) 819-24.						
	12.	Krupitza et al., "Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells", BRITISH JOURNAL OF CANCER, vol. 73, no. 4, 1 February 1996, pgs. 433-438.						
	13.	Ito et al., "Expression of receptor-type tryosine kinase, Ax1, and its ligand, gas6, in pediatric thyroid carcinomas around chernobyl", THYROID, vol. 12, no. 11, 1 November 2002, pgs. 971-975.						
	14.	Sasaki et al., "Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains", JOURNAL OF						

DT15 Rec'd FCT/PTO 1.8 JAN 2005

					Concete if Known		
INFORMATION DISCLOSURE					Application Numb	er	National Phase Zata 1 of PCT/EP2003/007786
STATEMENT BY APPLICANT				NT	Filing Date		Herewith
			First Named Inventor Axel ULLRICH et		Axel ULLRICH et al		
					Group Art Unit		
					Examiner Name		
				Confirmation No.			
Sheet of 3		3	Attorney Docket Number		2923-679		
	Pedrocchi et al., "Expression of CA2+-Binding Proteins of the S100 Family in malignant human breast-cancer cell lines and biopsy samples", INTERNATIONAL JOURNAL OF CANCER, vol. 57, no. 5, 1 June 1994, pgs. 684-690.						
Examiner Signature						Date Conside	red

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.